Publications by authors named "Fleurinck C"
Objective: To assess the effect of bimekizumab on pain, morning stiffness, and fatigue in patients with nonradiographic and radiographic axial spondyloarthritis (axSpA) in the phase III BE MOBILE studies (ClinicalTrials.gov: NCT03928704 and NCT03928743).
Methods: Patients were randomized to bimekizumab 160 mg or placebo every 4 weeks; and all patients received bimekizumab from week 16.
Background: Fatigue is an important symptom for most patients with axial spondyloarthritis (axSpA). The FACIT-Fatigue is a 13-item patient-reported outcome (PRO) instrument that has been used in axSpA clinical trials to measure fatigue severity and impact on daily activities. However, the psychometric properties of the FACIT-Fatigue are not fully evaluated across the entire spectrum of axSpA including non-radiographic axSpA (nr-axSpA) and radiographic axSpA (r-axSpA).
View Article and Find Full Text PDFArticle Synopsis
- Acute anterior uveitis is a common issue in patients with axial spondyloarthritis, and IL-17 plays a role in its development, but there's mixed evidence on how well IL-17A inhibitors work in treating it.
- This study pooled data from various clinical trials comparing the effects of bimekizumab (a monoclonal antibody that targets both IL-17A and IL-17F) and a placebo on the incidence of uveitis.
- Results showed that patients on bimekizumab had a significantly lower rate of uveitis compared to those receiving placebo, suggesting that bimekizumab may provide protective effects against uveitis in these patients.
Article Synopsis
- The study aimed to evaluate the effects of bimekizumab on physical function, sleep quality, work productivity, and overall health-related quality of life in patients with non-radiographic and radiographic axial spondyloarthritis. !* -
- Patients were randomly assigned to receive either bimekizumab or a placebo, with significant improvements observed in physical functioning and quality of life measures at Week 16, which were maintained or improved by Week 52. !* -
- The findings suggest that bimekizumab can provide early and sustained benefits across various aspects of health and well-being for patients with axial spondyloarthritis. !*
Article Synopsis
- The study aimed to evaluate how meeting specific clinical response criteria affects patient-reported outcomes in individuals with non-radiographic and radiographic axial spondyloarthritis after 52 weeks.
- It found that patients who achieved higher levels of clinical response (like ASAS40) experienced significantly greater improvements in core health areas such as pain, fatigue, and overall functioning compared to those with lower responses.
- The findings indicated that similar levels of improvement were seen in both non-radiographic and radiographic patients, suggesting effective treatment across different stages of the disease.
Article Synopsis
- Bimekizumab (BKZ) is an antibody that targets IL-17A and IL-17F, showing better effectiveness compared to a placebo in treating both non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) at Week 16, with a focus on its continued performance and safety by Week 52.
- In the BE MOBILE studies, patients were initially in a placebo-controlled phase for 16 weeks, followed by 36 weeks where all received BKZ, leading to sustained improvements in symptoms and inflammatory markers up to Week 52.
- At Week 52, the adverse event profiles showed no significant new safety concerns, with common issues including fungal infections
Article Synopsis
- Axial spondyloarthritis (axSpA) is a complex condition that requires new treatments, prompting two phase 3 trials (BE MOBILE 1 and BE MOBILE 2) to assess the effectiveness and safety of bimekizumab, a new drug targeting two interleukins (IL-17A and IL-17F).
- In these 52-week trials, patients with active nr-axSpA and r-axSpA were randomized to receive either bimekizumab or a placebo, with significant improvements observed at 16 weeks in the primary endpoint (ASAS40) and other measures of disease activity and inflammation.
- While bimekizumab showed positive effects, it was
Article Synopsis
- The study investigates the effects of the COVID-19 pandemic on disease activity and quality of life for patients with ankylosing spondylitis (AS) who were part of a clinical trial receiving bimekizumab treatment.
- Results showed that the majority of patients had stable health outcomes throughout the pandemic, with minimal disruption to their treatment.
- The findings suggest that the COVID-19 pandemic did not negatively impact disease activity or health-related quality of life for patients with AS in this study.
Article Synopsis
- The objective of the study was to evaluate the long-term safety, tolerability, and effectiveness of bimekizumab in patients with active ankylosing spondylitis over 156 weeks.
- The study involved patients who had previously taken part in a 48-week trial, where they received bimekizumab every four weeks during an open-label extension phase.
- Results indicated that a significant number of patients experienced side effects, notably respiratory infections, but the treatment remained effective, with over half of the participants showing substantial improvement in their condition by week 156.
Background: Respiratory syncytial virus (RSV) is the most common cause of severe lower respiratory tract infection, with a high global health burden. There are no effective treatments available. ALX-0171 is a novel trivalent Nanobody with antiviral properties against RSV.
View Article and Find Full Text PDFCirculating intercellular adhesion molecule-1 and E-selectin in acute ischemic stroke.
J Stroke Cerebrovasc Dis
December 2009
Exposure of endothelia to hypoxia followed by reperfusion, results in increased leukocyte activation and extravasation. These leukocytes potentiate ischemic neuronal damage. Extravasation of leukocytes is guided by adhesion molecule interactions on inflammatory and endothelial cells.
View Article and Find Full Text PDFTrovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia.
Antimicrob Agents Chemother
January 2000
The penetration of trovafloxacin (TVA), 200 mg once daily, into the airways of 17 patients with severe pneumonia was studied. The mean (standard deviations are given in parentheses) steady-state TVA concentrations, 2 h after the last intake, were 3.1 (0.
View Article and Find Full Text PDF